			Home About us Contact

Transient Myeloproliferative Disorder (transient + myeloproliferative_disorder)

Distribution by Scientific Domains

Medical Sciences	100%

Selected Abstracts

Hepatocyte growth factor in transient myeloproliferative disorder of Down syndrome

PEDIATRICS INTERNATIONAL, Issue 5 2009
Keiichi Hirono
No abstract is available for this article. [source]

Neonatal vesiculopustular eruption of the face: a sign of trisomy 21-associated transient myeloproliferative disorder

BRITISH JOURNAL OF DERMATOLOGY, Issue 6 2007
R. Moriuchi
No abstract is available for this article. [source]

Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome

BRITISH JOURNAL OF HAEMATOLOGY, Issue 5 2008
Tomohiko Sato
Summary JAK3 mutations have been reported in transient myeloproliferative disorder (TMD) as well as in acute megakaryoblastic leukaemia of Down syndrome (DS-AMKL). However, functional consequences of the JAK3 mutations in TMD patients remain undetermined. To further understand how JAK3 mutations are involved in the development and/or progression of leukaemia in Down syndrome, additional TMD patients and the DS-AMKL cell line MGS were screened for JAK3 mutations, and we examined whether each JAK3 mutation is an activating mutation. JAK3 mutations were not detected in 10 TMD samples that had not previously been studied. Together with our previous report we detected JAK3 mutations in one in 11 TMD patients. Furthermore, this study showed for the first time that a TMD patient - derived JAK3 mutation (JAK3I87T), as well as two novel JAK3 mutations (JAK3Q501H and JAK3R657Q) identified in an MGS cell line, were activating mutations. Treatment of MGS cells and Ba/F3 cells expressing the JAK3 mutants with JAK3 inhibitors significantly decreased their growth and viability. These results suggest that the JAK3 activating mutation is an early event during leukaemogenesis in Down syndrome, and they provide proof-of-principle evidence that JAK3 inhibitors would have therapeutic effects on TMD and DS-AMKL patients carrying activating JAK3 mutations. [source]